CHEK2 and metastatic prostate carcinoma: Indeed, it was observed that BRCAness was present in prostate cancer, colon cancer and pancreatic cancer [29,30,31], PARP inhibitor treatment improved survival of pancreatic cancer carrying mutated HRR deficient-related genes of ATM, BRCA1/2, CHEK2, PALB2, RAD51C, RAD51D [32], and enhanced treatment response in metastatic prostate cancer carrying mutated HRR deficient-related genes ATM, BRCA1/2, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD5C [33,34,35].